An assessment of the documentation for 30 over-the-counter diagnostic tests found none met the current regulatory standards.

The blood test is designed to detect the accumulation of amyloid protein deposits in the brain, a hallmark of Alzheimer's disease.

An assessment of the documentation for 30 over-the-counter diagnostic tests found none met the current regulatory standards.

The company said on Thursday that most of the increase came from organic revenues while acquisitions contributed to the company's growth.

The investment bank said that Exagen is poised for growth with a differentiated autoimmune test that outperforms conventional biomarker-based tests.

The test was developed in collaboration with Eli Lilly and can be used with other clinical information to rule out Alzheimer's disease as the cause of cognitive decline.

The cash deal includes ambulatory outreach laboratory services in 13 states and includes patient service centers and in-office phlebotomy sites.

Genetic Signatures also reported second quarter sales on par with the prior-year-quarter, reflecting higher respiratory testing in the Australian winter.

The firm posted before the market open on Tuesday results that beat expectations, and it raised its full-year revenue and earnings guidance.

The CEO submitted claims with codes for services that were never performed and received payments from more than one source for the same test.

The firm's life sciences revenues rose 1 percent, while diagnostics revenues were up 2 percent and biotechnology revenues jumped 8 percent.

The firm saw growth in its core laboratory segment but declines in molecular, point of care, and rapid diagnostics.